Various tissue-specific antibodies have been attached to nanoparticles to obtain targeted delivery. In particular, nanodelivery systems with selectivity for breast, prostate and cancer tissue have been developed. Here, we have developed a nanodelivery system that targets the thyroid gland. Nanoliposomes have been conjugated to the thyroid-stimulating hormone (TSH), which binds to the TSH receptor (TSHr) on the surface of thyrocytes. The results indicate that the intracellular uptake of TSHnanoliposomes is increased in cells expressing the TSHr. The accumulation of targeted nanoliposomes in the thyroid gland following intravenous injection was 3.5-fold higher in comparison to untargeted nanoliposomes. Furthermore, TSH-nanoliposomes encapsulated with gemcitabine showed improved anticancer efficacy in vitro and in a tumor model of follicular thyroid carcinoma. This drug delivery system could be used for the treatment of a broad spectrum of thyroid diseases to reduce side effects and improve therapeutic efficacy.
Introduction
The field of targeted therapy was born from the introduction of the "magic bullet" concept, which entails the selective delivery of a drug to a tissue of interest [1] . The concept involves reducing side effect, broadening the therapeutic window and increasing drug efficacy, through the selective delivery of an agent to a specific site in the body. Such selectivity is especially desired for diseases characterized by a low therapeutic index, such as cancer. Among various approaches adopted for drug delivery [2e5], liposomes provide a strategy for improving the biopharmaceutical properties of drugs [6e8] . In particular, pegylated liposomes can avoid immunological recognition and rapid clearance by macrophages [9e11] . Accordingly, several liposomal formulations have gained clinical approval and many more are currently undergoing clinical trials [12] . In an attempt to achieve selectivity, antibodies that are specific for surface molecules on target cells have been conjugated to liposomes. For instance, an antibody fragment against the human epidermal growth factor receptor 2 (HER2), frequently expressed in breast cancer, has been attached to liposomes [13] . Similarly, liposomes have been coated with the monoclonal antibody (mAb) 2C5, which binds to nucleosomes on the surface of cancer cells [14] . In addition, folate-moieties have been incorporated in supramolecular vesicular aggregates to obtain preferential uptake by cancer cells that express the folate receptor [15, 16] .
Although several tissue-specific antibodies have been conjugated to nanoparticles, there are several organs, such as the thyroid gland, that have not been the focus of targeted drug delivery. We propose a strategy for obtaining preferential accumulation of nanoparticles in the thyroid. Thyroid-stimulating hormone (TSH) has been attached to the surface of pegylated nanoliposomes with the aim of targeting the TSH receptor (TSHr). The TSHr is a glycoprotein G-protein-coupled receptor expressed in the plasma membrane of thyrocytes. This receptor binds to TSH with high affinity and specificity and mediates the ligands biological effects on the thyroid gland [17] . TSHr expression is maintained in most thyroid pathologies, including benign and malignant tumors [18e 23]. More importantly, the receptor is also present in the majority of less differentiated and more aggressive tumors [18e23], making it an optimal target for the delivery of chemotherapeutics. . Microflow tees, PEEKÔ unions and tees were from Upchurch Scientific (Oak Harbor, WA). The stationary phase used for packing the nanoscale LC column was 3 mm C 18 provided by Dr. Maisch (Entringen, Germany). Zip TipsÔ with strong cation exchange (SCX) properties were purchased from Millipore (Billerica, MA). Oasis HLB 1 cc (10 mg) solid phase extraction (SPE) cartridges were from Waters (Milford, MA). Gemcitabine (2,2I-difluorodeoxycytidine) hydrochloride (HPLC purity >99%) was a gift from Eli-Lilly Italia S.p.A. (Sesto Fiorentino, Firenze, Italy), and was used without further purification. FTC-133 human follicular thyroid carcinoma cells were purchased from SigmaeAldrich (S.r.l. Milan, Italy) and Chinese hamster ovary (CHO) cells were provided by ATCC (Teddington, Middlesex, UK).
Preparation of TSH-nanoliposomes
Nanoliposomes were made from DPPC/cholesterol/DSPEmPEG2000/DSPEmPEG2000-PDP (6:3:0.6:0.4 M ratio). The lipid mixture (20 mg) was dissolved in a round-bottom flask, using a chloroform/methanol mixture (3:1 v/v). Fluoresceinlabeled and radiolabelled nanoliposomes where obtained by adding fluorescein-DHPE (0.1% molar) or [ 3 H]CHE to the lipid mixture. The organic solvents were removed with a rotary evaporator (Büchi R-210 Switzerland), followed by overnight incubation in a Büchi T51 glass-drying oven connected to a vacuum pump. Multilamellar nanoliposomes were prepared by hydrating the lipid film with 1 mL of saline solution (NaCl 0.9% w/v) and performing three alternate cycles (3 min each) of heating at 58 C (water bath) and vortex mixing at 700 rpm. To reduce the disulfide bond the nanoliposomes were incubated with a 50 mM DTT solution (1:2 v/v respectively) for 30 min. Excess DTT was then removed after centrifugation at 20,000 Â g for 60 min at 4 C with a Beckman Coulter Allegra 64R centrifuge. Successively, the pellet was resuspended in 250 mM ammonium sulfate solution (1 mL) and subjected to ten cycles of freezing (liquid nitrogen) and thawing (water bath at 40 C), thus achieving a pH gradient with an acid environment in the aqueous compartment.
The nanoliposomes were further extruded through polycarbonate filters with pore sizes of 400 nm, 200 nm and 100 nm (Costar, Corning Incorporated, NY, USA) using a stainless steel extrusion device (Lipex Biomembranes, Vancouver, BC, USA). Unentrapped ammonium sulfate solution was removed by centrifugation. Gemcitabine loading was achieved by incubating nanoliposomes for 3 h at room temperature in an isotonic solution (1 mL) of gemcitabine-hydrochloride (1 mM). Unentrapped drug was removed by gel permeation chromatography. The 3-(2-pyridyldithio)propionate (PDP) moieties on the liposomal surface were reduced and conjugated to TSH (2.5 mg/mL nanoliposomes) through overnight incubation.
TSH-nanoliposome purification
Unentrapped gemcitabine and unconjugated TSH were removed by gel permeation chromatography using an ÄKTA prime PLUS (Amersham Biosciences, Uppsala, Sweden), equipped with an UV detector at fixed wavelengths (254 nm and 280 nm). The purification procedure was performed at room temperature using a XK16/20 column (Amersham Biosciences, Uppsala, Sweden) with Sephadex G-25 as the stationary phase and a saline solution as the eluent. The column had an equilibration volume of 80 mL and the flow rate was 0.5 mL/min. The amount of unentrapped gemcitabine was determined spectrophotometrically with l max (wavelength) at 268.8 nm using a Perkin Elmer Lambda 20 UV-Vis spectrophotometer (Uberlingen, Germany) equipped with Perkin Elmer UV WinLabÔ ver. 2.8 acquisition software (Uberlingen, Germany).
Sample preparation for liquid chromatography-tandem mass analysis spectrometry
To obtain a reference value, human TSH (2.5 mg in 5 mL) was diluted with 20 mL of digestion buffer composed of 0.2% (v/v) SDS and 200 mM tris(hydroxymethyl)aminomethane (Tris, pH 8.5). The protein was reduced by adding 100 mM DTT (2.5 mL) and incubating the mixture for 1 h at 37 C. Cysteines were then alkylated by adding 3 mL of 200 mM freshly prepared iodoacetamide solution in water and incubating the mixture for 1 h at 37 C. Finally, excess iodoacetamide was neutralized by adding 0.5 mL of 100 mM DTT. The solution was brought to a volume of 100 mL by adding LC water, and trypsin was added (500 ng) to allow enzymatic digestion. Before performing LC coupled to tandem MS (LC-MS/MS) analysis, 3 mL of digested TSH was diluted with 27 mL of solution SCX1, composed of acetonitrile/water/formic acid (80:19.9:0.1 v/v/v), and purified by ZipTips SCX following a slightly modified procedure, with respect to the manufacturer's instructions. Briefly, ZipTips were equilibrated with solution SCX1 and then used to concentrate the peptide mixture through at least five cycles of aspiration/discarding (aspiration volume 10 mL). After 5 Â 10 mL washes with solution SCX1, the detergent-free peptide mixture was eluted in 2 mL of water/methanol/ammonium hydroxide solution (80:15:5, v/v/v). The sample was then diluted in 28 mL of loading pump solvent.
In order to evaluate whether the conjugation of TSH hormone with nanoliposomes was successful, the formulation was washed three times and then incubated with DTT (10 mM) and Tris (100 mM). The supernatants from the last wash (control) and nanoliposomes incubated with DTT were analyzed. Proteins were reduced, alkylated, and digested, as described in the section above. The samples were concentrated by SPE. Briefly, the SPE column (beads, 10 mg) was conditioned with 500 mL of water/methanol 1/1 (v/v); the column was then equilibrated with 500 ml of water/methanol/trifluoroacetic acid (TFA) (97. 
LC-MS/MS analysis and database search
Chromatography was performed on an Ultimate Nano LC System from Dionex (Sunnyvale, CA) using a valveless setup [24] . 10 mL of sample was loaded in an inhouse packed 75 mm ID, 4 cm long Integra FritÔ trapping column (1 cm packing bed length) at 12 mL/min of loading pump solvent consisting of water/acetonitrile/ trifluoroacetic acid (TFA) (97.95:2:0.05 v/v/v). After 4 min of washing, the trapping column was switched online to the analytical in-house packed 50 mm ID, 12 cm long Pico FritÔ column filled with 3 mm C 18 silica particles, and gradient separation was MS detection was performed on a QSTAR XL hybrid LC-MS/MS from Applied Biosystems (Foster City, CA), operating in positive ion mode with electro-spray potential at 1800 V, curtain gas at 15 units and collisionally activated dissociation (CAD) gas at 3 units. Information dependent acquisition (IDA) was done by selecting the four most abundant peaks for analysis after a full time of flight (TOF)-MS scan from 350 to 1400 m/z lasting 3 s. The threshold value for the peak selection for MS/ MS was 25 counts. MS/MS analysis was performed in enhanced mode (3 s/scan).
Data were searched on the Mascot search engine (www.matrixscience.com) against the SwissProt database using the following parameters: MS tolerance 100 ppm; MS/MS tolerance 0.3 Da; fixed modifications carbamidomethyl cysteine; variable modifications methionine oxidized; enzyme trypsin; maximum missed cleavages 2; taxonomy human.
Physicochemical characterization of TSH-nanliposomes
The physicochemical properties of TSH-nanoliposomes were characterized using a Zetasizer Nano ZS (Malvern Instruments Ltd., Worchestershire, United Kingdom) as previously reported [7] . Briefly, samples were diluted 1:50 in isotonic saline solution (NaCl 0.9% w/v) to avoid multiscattering. The average size and narrow size distribution was measured using photon correlation spectroscopy. The instrument was equipped with a 4.5 mW laser diode operating at 670 nm. Scattered photons were detected at 173 . The third-order cumulant fitting autocorrelation function was applied to achieve mean sizes and size distribution profiles from scattered photon patterns. The following parameters were used: real refractive index 1.59, imaginary refractive index 0.0, medium refractive index 1.330, medium viscosity 1.0 mPa Â s and medium dielectric constant 80.4. The zeta potential was measured using the Doppler laser anemometry. The apparatus was equipped with a He/Ne laser doppler anemometry (633 nm) with nominal power of 5.0 mW. A Smoluchowsky constant F (Ka) of 1.5 was applied during analysis. For each sample five measurements were taken with 15 runs per measurement. Results are the average AE standard deviation.
For freeze fracture electron microscopy analysis, samples were centrifuged at 30,000 Â g for 30 min at room temperature (Microcentrifuge Ole Dich. Denmark), impregnated with 30% (v/v) glycerol, and then frozen in partially solidified Freon 22. The samples were freeze fractured in a freeze fracture device (105 C, 10-6 mm Hg) and replicated by evaporation from a platinum/carbon gun. The replicas were extensively washed with distilled water, picked up onto Formvar coated grids and examined with a Philips CM 10 transmission electron microscope, as previously reported [25] .
Cell culture
To evaluate the selectivity of the TSH-nanoliposomes against cells expressing the TSHr, CHO wild type cells without TSHr (CHO-w) and CHO cells transfected with TSHr (CHO-t) were used. TSHr transfection was performed as previously reported [26] . CHO cells were incubated (Guaire Ò TS Autoflow Codue Water-JacketedIncubator) with F12 medium containing penicillin (100 UI/mL), streptomycin (100 mg/mL) and FBS (10%, v/v). FTC-133 human thyroid carcinoma cells were incubated with DMEM/F12 (1:1 v/v) supplemented with glutamate, D-glucose, pyruvate, 10% FBS (v/v), penicillin (100 UI/mL), and streptomycin (100 mg/mL). The medium was replaced every 48 h.
Intracellular accumulation of TSH-nanoliposomes
The intracellular accumulation of radiolabeled [ 3 H]CHE TSH-nanoliposomes and control nanoliposomes in CHO-w cells (do not express TSHr) and CHO-t cells (express TSHr) was measured as a function of time. [ 3 H]CHE was used at a concentration of 0.003% v/v, which corresponds to 3 nmol of [ competitive binding to the hormone receptor. After a 3 h incubation period, cells were centrifuged (1200 rpm at room temperature for 10 min) and the culture medium was removed. Cells were washed twice with phosphate buffered saline (PBS) and transferred into polypropylene liquid scintillation vials (SigmaeAldrich Chemie, GmbH, Steinheim, Germany). Cells were then dissolved in a quaternary ammonium hydroxide solution (2 mL, BTS-450, Beckman Instruments, Inc., Fullerton, Netherlands) under continuous shaking for 1 h at 60 C, using an incubator shaker (InnovaÔ 4300, New Brunswick Scientific, Edison, NJ, USA). At the end of the incubation time, the liquid scintillation cocktail (7 mL, Ready OrganicÔ, Beckman Coulter Inc., Fullerton, USA) was added to the solution and the samples were vigorously mixed and analyzed using a Wallac Win SpectralÔ 1414 liquid scintillation counter (PerkinElmer Life and Analytical Sciences, Inc. Waltham, MA, USA). 1414 Win Spectral Wallac LCS Software was used for data analysis.
Confocal laser scanning microscopy
The intracellular uptake of fluorescein-labeled TSH-nanoliposomes was measured in CHO and FTC-133 cells using confocal laser scanning microscopy (CLSM). Cells (4 Â 10 5 cells/ml) were placed in 6-well culture plates with culture medium and a sterile glass slide was positioned in each well. Plates were incubated for 24 h followed by treatment with fluorescein-labeled nanoliposomes for 2 h. Each well was then washed with PBS (3 times) to remove excess nanoliposomes and cells were fixed on a sterile glass slide, using 1 mL of an ethanol solution (70%, v/v). Each slide was washed again with PBS (3 times) and treated with 1 mL of Hoechst solution (1/1000), incubated for 5 min and then washed with PBS (3 times, 2 mL). Plates were stored at 4 C prior to CLSM analysis. CLSM was carried out using a Leika TCS SP2 MP 
In vitro anticancer activity
The in vitro anticancer activity of free gemcitabine and gemcitabine-loaded nanoliposomes or TSH-nanoliposomes was evaluated using a MTT assay. Cells were plated into 96-well culture dishes (5 Â 10 3 cells/0.2 mL) and incubated for 24 h.
Cells were then treated with free drug or nanoliposomes (8 wells/group) and incubated for 24 h, 48 h or 72 h. Untreated cells were used as a control. Cells were then incubated for 3 h in tetrazolium salt dissolved in PBS solution (10 mL, 5 mg/mL).
The medium was removed and formazan crystals, which precipitated at the bottom of the well after mitochondrial oxidation, were dissolved with 
LC quantification
LC analysis was performed using a system from Varian Inc. (Palo Alto, CA, USA), composed of a 200-2031 Metachem online degasser, a M210 binary pump, a ProStar 410 autosampler, a G1316A thermostat column compartment and a 25 mL CSL20 Cheminert Sample Loop injector. Data was acquired and processed with a Galaxie Ò chromatography manager software (Varian Inc.). Chromatographic separation was carried out at room temperature using a GraceSmart RP C18 column (4.6 Â 250 mm, 5 mm particle size, Alltech Grom GmbH, Rottenburg-Hailfingen, Germany). The mobile phase was water/acetonitrile (95:5 v/v). The flow rate was 1 mL/min and detection was performed at wavelength of 269 nm.
Quantification of gemcitabine was done using a standard curve in the linear concentration range of 0.1 ng/mL to 10 mg/mL. The amount of gemcitabine was determined according to the following equation:
where x is the drug concentration (mg/mL) and AUC the area under the curve (mAu Â min).
Animals
In vivo experiments were performed according to the principles and procedures outlined by the local Ethical Committee and the European Communities Council Directive of 24 November 1986 (86/609/EEC). Animals were maintained at standard temperature (20 AE 2 C) and humidity (65%) conditions with 12 h light/12 h dark cycles and food and water ad libitum. Wistar rats and nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice were purchased from Harlam (Italy s.r.l. San Pietro al Natisone (UD), Italy).
In vivo biodistribution
Biodistribution experiments were performed in female Wistar rats (4e5 months old, 200e250 g). 
In vivo anticancer efficacy and tumor accumulation
FTC-133 cells (1 Â 10 6 cells/mL) were cultured using a previously reported protocol [27] and diluted into 200 mL of sterile isotonic PBS (Harlan Italy S.r.l., San
Pietro al Natisone (UD), Italy). The cells were injected subcutaneously into female NOD SCID mice (4e6 weeks old, 20e22 g) and treatment was initiated when the average tumor volume reached w500 mm 3 (w8e10 mm in diameter). Mice were divided into the following five treatment groups (5 mice/group): PBS, gemcitabine, gemcitabine-loaded nanoliposomes, and gemcitabine-loaded TSH-nanoliposomes. Free gemcitabine and both formulations containing gemcitabine nanoliposomes were administered intravenously (200 mL) at a gemcitabine dose of 5 mg/kg/day for 14 days. The tumor volume was measured every two days according to the following equation:
where Vt is tumor volume, D and d are the long and short tumor diameter. Mice were sacrificed and tumors were collected 15 days after treatment initiation. Tumor accumulation studies were performed using the same tumor model as in the anticancer efficacy studies. When the average tumor volume reached w500 mm 3 (w8e10 mm in diameter), mice were injected through the tail vein 
Results and discussion

Synthesis and assembly of TSH-nanoliposomes
TSH-nanoliposomes were prepared by conjugating the amino acid residue of cysteine in the TSH hormone with a thiolactivated moiety present on the surface of the nanoliposome, thereby forming a disulfide bond (Fig. 1) . The formation of the conjugate was confirmed with LC-MS/MS ( Supplementary  Figs. S1 and S2) . A small aliquot of pure TSH was digested and analyzed to generate a list of TSH specific peptides detectable by mass spectrometry. A database search of MS/MS data allowed for high-confidence identification of four specific peptides, three of which belonged to the alpha-subunit and one of which belonged to the beta-subunit (Supplementary Table S1 ). Selected ion chromatograms (SICs) for two out of the four peaks could be detected in the nanoliposome sample, whereas none of the peaks were present in the control sample. The amount of TSH peptide recovered from the nanoliposome surface was probably below the detection limit for the two peaks that did not show up during analysis. Supplementary Figs. S1 and S2 show SICs of those m/z giving a positive signal, which were ions at m/z 419.73 (peptide VTVMGGFK, belonging to alpha-chain of the TSH) and 688.32 (peptide ALSQDVCTYR, belonging to the beta-chain of the TSH). Moreover, the MS/MS spectrum acquired under the peak in datadependent mode (Supplementary Figs. S1c and S2c) strongly resembles that of the MS/MS spectrum acquired from standard human TSH (Supplementary Figs. S1d and S2d) . The data indicates that TSH was successfully conjugated to the surface of nanoliposomes.
Physicochemical characterization of TSH-nanoliposomes
A small size and a narrow size distribution is desired for colloidal drug delivery systems [28, 29] . Here, photon correlation spectroscopy showed that the untargeted nanoliposomes and the TSH-nanoliposomes had a mean diameter of 141.8 nm (Supplementary Fig. S3 ) and 148.2 nm (Fig 1b) , respectively. The small size increase following TSH conjugation suggests that thy hydrodynamic radius was increased due to the presence of an additional hydrophilic molecule on the liposomal surface. Furthermore, freeze-fracture transmission electron microscopy was performed to confirm the size-range of the particles (Fig. 1d) . Gemcitabine-loaded nanoliposomes were not separately characterized, as it has previously been show that gemcitabine encapsulation does not affect the mean size and size distribution of vesicular carriers [30] . Both targeted and untargeted formulations exhibited a narrow size distribution (Fig 1b  and Supplementary Fig. S3 ). The addition of TSH to the nanoliposomes influenced the surface characteristics of the vesicular carrier, resulting in a reduction of the zeta potential from À15 mV to À34 mV (Fig. 1c) .
Intracellular uptake and in vitro cytotoxicity of TSHnanoliposomes
The selectivity of TSH-nanoliposomes for cells expressing the TSHr was evaluated in wild-type CHO cells lacking the TSHr (CHOw) and in CHO cells transfected with the TSHr (CHO-t). [ 3 H]CHEradiolabeled TSH-nanoliposomes displayed enhanced cellular uptake in CHO-t cells in comparison to CHO-w cells, while the uptake of untargeted nanoliposomes was similar in both cell lines (Fig. 2a  and b) . Experiments evaluating the competitive binding of free TSH and nanoliposomes with TSHr on the cell surface were carried out using increasing doses of TSH (Fig. 2c) . In the case of TSHnanoliposomes, the cellular uptake in CHO-t cells decreased as the dose of free TSH increased, while the cellular internalization of unconjugated nanoliposomes was independent of free TSH. Accordingly, confocal laser scanning microscopy showed that fluoresceine-labeled TSH-nanoliposomes were internalized to a greater extent in CHO-t cells, as compared to untargeted nanoliposomes (Fig. 2d ). These findings demonstrate the active targeting ability of the TSH-nanocarrier on the cellular level.
The cytotoxicity of empty TSH-nanoliposomes and control nanoliposomes was evaluated in CHO cells. The results indicate that the empty delivery system does not reduce cell viability (Supplementary Fig. S4 ). The cell viability remained over 95%, even when the empty nanoliposome was administered at high concentrations, demonstrating the in vitro biocompatibility of the delivery system.
Comparative biodistribution of TSH-nanoliposomes and control nanoliposomes
The comparative biodistribution of [ 3 H]CHE-radiolabeled TSHnanoliposomes and control nanoliposomes in Wistar rats was evaluated. The results demonstrate a three-fold increase in the accumulation of the TSH-nanoliposomes in the thyroid, as compared to the untargeted nanoliposomes (Fig. 3) . The conjugation of TSH to the liposomal surface did not increase the accumulation of nanoliposomes in other organs, including the liver, spleen, heart, lungs and kidney (Fig. 3) , thus demonstrating in vivo selectivity for the TSHr in the thyroid gland.
In vitro anticancer efficacy of gemcitabine-loaded TSHnanoliposomes
Next, TSH-nanoliposomes were evaluated as drug delivery systems for gemcitabine, an anticancer drug widely investigated as a candidate for liposomal delivery [15,16,27,30e32] . The cytotoxicity of this chemotherapeutic agent was examined in vitro in CHO cells, which were transfected with TSHr and in FTC-133 cells, which endogenously express TSHr. In general, gemcitabine-loaded nanoliposomes displayed greater anticancer efficacy to that of the free drug (Fig. 4 and Supplementary Fig. S4 ). In CHO-w cells there was no apparent difference between the cytotoxicity of gemcitabineloaded targeted or untargeted nanoliposomes ( Supplementary  Fig. S4 ). However, in CHO-t cells the TSH-nanoliposomes outperformed the control nanoliposomes, in terms of reducing cell viability. For instance, after 72 h at a concentration of 1 mM gemcitabine, cells incubated with targeted nanoliposomes and untargeted nanoliposomes had a cell viability of w28% and w56%, respectively ( Supplementary Fig. S4 ). Similarly, in FTC-133 cells, after 48 h at a concentration of 0.1 mM gemcitabine, cells incubated with TSH-nanoliposomes and control nanoliposomes had a cell viability of 11% and 36%, respectively (Fig. 4a) . In this context, it was also demonstrated that the conjugation of TSH to nanoliposomes increased their intracellular uptake in FTC-133 cells (Fig. 4bed) . Accordingly, the intracellular concentration of gemcitabine also increased when targeted nanoliposomes were used as a delivery vehicle in comparison to untargeted nanoliposomes (Fig. 4e) . Moreover, the intracellular accumulation of TSH-nanoliposomes decreased as the concentration of free TSH increased in the media (Fig. 4b ). Competitive binding with the free ligand confirms that the major mechanism for cellular internalization is mediated by binding of the delivery system to TSHr. The results demonstrate that the conjugation of TSH can markedly improve the anticancer efficacy of gemcitabine-loaded nanoliposomes in cells expressing TSHr.
In vivo anticancer activity and tumor accumulation of gemcitabine-loaded TSH-nanoliposomes
A subcutaneous tumor model of follicular thyroid carcinoma (FTC-133 cells) was used to evaluate the in vivo anticancer efficacy of gemcitabine-loaded TSH-nanoliposomes. The nanoliposomes were radiolabeled ([ 3 H]CHE) to measure tumor accumulation upon intravenous injection. As is evident from Fig. 5a , the presence of the TSH on the liposomal surface allowed for increased accumulation of the delivery vehicle in the tumor. For instance, 1 h post administration, the TSH-nanoliposomes were present in the tumor at an almost two-fold higher level than the unconjugated nanoliposomes. Furthermore, the in vivo anticancer activity of gemcitabine-loaded nanoliposomes was evaluated. Gemcitabineloaded TSH-nanoliposomes elicited the greatest reduction in tumor growth. Indeed, after 14 days of treatment, a significant difference in tumor volume and weight was evident between groups receiving gemcitabine-loaded TSH-nanoliposomes or gemcitabineloaded control nanoliposomes ( Fig. 5b and c) . The anticancer efficacy is further illustrated in photographs of dissected tumor samples (Fig. 5d) . Taken together, the results demonstrate that TSHnanoliposomes are an effective delivery platform for targeting thyroid tissue in vivo. We envision that TSH-nanoliposomes could be used to deliver a variety of therapeutic agents. In particular, both hydrophilic and hydrophobic therapeutics can be loaded inside liposomes [33e36] . For instance, TSH-nanoliposomes could also be used for the delivery of antithyroid drugs to benign lesions, such as thyroid hyper-functioning adenomas [37] .
Conclusions
We have developed a nanodelivery system consisting of nanoliposomes conjugated to the TSH. This delivery system is designed to target cells expressing the TSHr, which is frequently found in normal thyroid tissue and in a large number of thyroid carcinomas. Indeed, TSH-nanoliposomes displayed increased cellular uptake in comparison to control nanoliposomes in cells with TSHr. In addition, targeted nanoliposomes had higher levels of accumulation in normal thyroid tissue and in subcutaneous thyroid tumors. Furthermore when TSH-nanoliposomes were loaded with gemcitabine the in vitro and in vivo anticancer efficacy was markedly improved. Herein, we have demonstrated a valid delivery platform for obtaining enhanced deposition of drugs in thyroid tissue following systemic injection.
